Bloomberg @business
U.S. health officials are pleading for more use of Covid-19 antibody therapies from Eli Lilly and Regeneron Pharmaceuticals that have been plagued by logistical issues, lack of efficacy data and insufficient reimbursement https://t.co/4bd2hxKhRi — PolitiTweet.org